Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
- 24 October 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 17 (11), 2178-2182
- https://doi.org/10.1038/sj.leu.2403138
Abstract
A total of 31 adult patients with AML entered in the EORTC/GIMEMA AML-10 trial, who received autologous stem cell transplantation (ASCT) after induction and consolidation chemotherapy, were prospectively evaluated for minimal residual disease (MRD) by multidimensional flow cytometry (MFC). Using a cutoff level of 3.5 x 10(-4) leukemic cells pre-ASCT, 12 patients (39%) were stratified to MRD high-risk group and 19 (61%) into MRD low-risk group. During follow-up, all patients who were in the high-risk group relapsed at a median time of 7 months; in the low-risk group, five patients relapsed at a median time of 11 months and 14 remained in remission for 56 (range 7-80) months (P=0.00004). Longitudinal MFC determinations post-ASCT showed increased MRD levels in three of the five patients who underwent subsequent relapse, while disease recurrence was unpredicted in the remaining two cases. The pre-ASCT MRD status was the factor most strongly associated with relapse risk in the multivariate analysis (P=0.0014). We conclude that: (1) pre-ASCT MRD status predicts successful outcome in patients receiving ASCT; (2) high-dose chemotherapy conditioning regimen followed by ASCT has no impact on the unfavorable prognostic value of high pre-ASCT MRD level; and (3) sequential MRD monitoring post-ASCT may allow the prediction of impending relapseKeywords
This publication has 18 references indexed in Scilit:
- Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemiaBlood, 2002
- How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administrationLeukemia, 2002
- Clinical Relevance of Minimal Residual Disease Detection in Adult Acute Myeloid LeukemiaJournal of Hematotherapy & Stem Cell Research, 2002
- Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratificationBlood, 2001
- Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First RemissionNew England Journal of Medicine, 1998
- Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trialThe Lancet, 1998
- Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemiaThe Lancet, 1998
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.Journal of Clinical Oncology, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958